Helen Kim1, Jeffrey Nelson2, Timo Krings2, Karel G terBrugge2, Charles E McCulloch2, Michael T Lawton2, William L Young2, Marie E Faughnan2. 1. From the Departments of Anesthesia and Perioperative Care (H.K., J.N., W.L.Y.), Epidemiology and Biostatistics (H.K., C.E.M.), and Neurological Surgery (M.T.L., W.L.Y.), University of California, San Francisco; Division of Neuroradiology, Department of Medical Imaging (T.K., K.G.T.), Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada; and Division of Respirology, Keenan Research Centre, and Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada (M.E.F.). kimhel@anesthesia.ucsf.edu. 2. From the Departments of Anesthesia and Perioperative Care (H.K., J.N., W.L.Y.), Epidemiology and Biostatistics (H.K., C.E.M.), and Neurological Surgery (M.T.L., W.L.Y.), University of California, San Francisco; Division of Neuroradiology, Department of Medical Imaging (T.K., K.G.T.), Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada; and Division of Respirology, Keenan Research Centre, and Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada (M.E.F.).
Abstract
BACKGROUND AND PURPOSE: Hereditary hemorrhagic telangiectasia (HHT) is a systemic disease characterized by mucocutaneous telangiectasias, epistaxis, and arteriovenous malformations (AVMs). Intracranial hemorrhage (ICH) rates in this population are not well described. We report ICH rates and characteristics in HHT patients with brain AVMs (HHT-BAVMs). METHODS: We studied the first 153 HHT-BAVM patients with follow-up data enrolled in the Brain Vascular Malformation Consortium HHT Project. We estimated ICH rates after BAVM diagnosis. RESULTS: The majority of patients were women (58%) and white (98%). The mean age at BAVM diagnosis was 31±19 years (range, 0-70), with 61% of cases diagnosed on asymptomatic screening. Overall, 14% presented with ICH; among symptomatic cases, 37% presented ruptured. During 493 patient-years of follow-up, 5 ICH events occurred yielding a rate of 1.02% per year (95% confidence interval, 0.42-2.44%). ICH-free survival differed significantly by ICH presentation (P=0.003); ruptured cases had a higher ICH rate (10.07%; 95% confidence interval, 3.25-31.21%) than unruptured cases (0.43%; 95% confidence interval, 0.11-1.73%). CONCLUSIONS: Patients with HHT-BAVM who present with hemorrhage are at a higher risk for rehemorrhage compared with patients with BAVM detected presymptomatically.
BACKGROUND AND PURPOSE:Hereditary hemorrhagic telangiectasia (HHT) is a systemic disease characterized by mucocutaneous telangiectasias, epistaxis, and arteriovenous malformations (AVMs). Intracranial hemorrhage (ICH) rates in this population are not well described. We report ICH rates and characteristics in HHTpatients with brain AVMs (HHT-BAVMs). METHODS: We studied the first 153 HHT-BAVM patients with follow-up data enrolled in the Brain Vascular Malformation Consortium HHT Project. We estimated ICH rates after BAVM diagnosis. RESULTS: The majority of patients were women (58%) and white (98%). The mean age at BAVM diagnosis was 31±19 years (range, 0-70), with 61% of cases diagnosed on asymptomatic screening. Overall, 14% presented with ICH; among symptomatic cases, 37% presented ruptured. During 493 patient-years of follow-up, 5 ICH events occurred yielding a rate of 1.02% per year (95% confidence interval, 0.42-2.44%). ICH-free survival differed significantly by ICH presentation (P=0.003); ruptured cases had a higher ICH rate (10.07%; 95% confidence interval, 3.25-31.21%) than unruptured cases (0.43%; 95% confidence interval, 0.11-1.73%). CONCLUSIONS:Patients with HHT-BAVM who present with hemorrhage are at a higher risk for rehemorrhage compared with patients with BAVM detected presymptomatically.
Authors: R P Atkinson; I A Awad; H H Batjer; C F Dowd; A Furlan; S L Giannotta; C R Gomez; D Gress; G Hademenos; V Halbach; J C Hemphill; R T Higashida; L N Hopkins; M B Horowitz; S C Johnston; M W Lawton; M W McDermott; A M Malek; J P Mohr; A I Qureshi; H Riina; W S Smith; J Pile-Spellman; R F Spetzler; T A Tomsick; W L Young Journal: Stroke Date: 2001-06 Impact factor: 7.914
Authors: Aditya Bharatha; Marie E Faughnan; Helen Kim; Tony Pourmohamad; Timo Krings; Pinar Bayrak-Toydemir; Ludmila Pawlikowska; Charles E McCulloch; Michael T Lawton; Christopher F Dowd; William L Young; Karel G Terbrugge Journal: Stroke Date: 2011-10-27 Impact factor: 7.914
Authors: C L Shovlin; A E Guttmacher; E Buscarini; M E Faughnan; R H Hyland; C J Westermann; A D Kjeldsen; H Plauchu Journal: Am J Med Genet Date: 2000-03-06
Authors: Amy L Akers; Karen L Ball; Marianne Clancy; Anne M Comi; Marie E Faughnan; Rashmi Gopal-Srivastava; Thomas P Jacobs; Helen Kim; Jeffrey Krischer; Douglas A Marchuk; Charles E McCulloch; Leslie Morrison; Marsha Moses; Claudia S Moy; Ludmilla Pawlikowska; William L Young Journal: J Rare Disord Date: 2013-04-01
Authors: J P Mohr; Michael K Parides; Christian Stapf; Ellen Moquete; Claudia S Moy; Jessica R Overbey; Rustam Al-Shahi Salman; Eric Vicaut; William L Young; Emmanuel Houdart; Charlotte Cordonnier; Marco A Stefani; Andreas Hartmann; Rüdiger von Kummer; Alessandra Biondi; Joachim Berkefeld; Catharina J M Klijn; Kirsty Harkness; Richard Libman; Xavier Barreau; Alan J Moskowitz Journal: Lancet Date: 2013-11-20 Impact factor: 79.321
Authors: Helen Kim; Rustam Al-Shahi Salman; Charles E McCulloch; Christian Stapf; William L Young Journal: Neurology Date: 2014-07-11 Impact factor: 9.910
Authors: Li Ma; Fanxia Shen; Kristine Jun; Chen Bao; Robert Kuo; William L Young; Stephen L Nishimura; Hua Su Journal: Transl Stroke Res Date: 2016-06-29 Impact factor: 6.829
Authors: Peter B Sporns; Heather J Fullerton; Sarah Lee; Helen Kim; Warren D Lo; Mark T Mackay; Moritz Wildgruber Journal: Nat Rev Dis Primers Date: 2022-02-24 Impact factor: 52.329
Authors: Ali Tayebi Meybodi; Helen Kim; Jeffrey Nelson; Steven W Hetts; Timo Krings; Karel G terBrugge; Marie E Faughnan; Michael T Lawton Journal: Neurosurgery Date: 2018-01-01 Impact factor: 4.654
Authors: Christoph J Griessenauer; Sean Farrell; Atom Sarkar; Ramin Zand; Vida Abedi; Neil Holland; Andrew Michael; Christopher L Cummings; Raghu Metpally; David J Carey; Oded Goren; Neil Martin; Philipp Hendrix; Clemens M Schirmer Journal: J Cereb Blood Flow Metab Date: 2018-09-05 Impact factor: 6.200
Authors: Omer F Eker; Edoardo Boccardi; Ulrich Sure; Maneesh C Patel; Saverio Alicante; Ali Alsafi; Nicola Coote; Freya Droege; Olivier Dupuis; Annette Dam Fialla; Bryony Jones; Ujwal Kariholu; Anette D Kjeldsen; David Lefroy; Gennaro M Lenato; Hans Jurgen Mager; Guido Manfredi; Troels H Nielsen; Fabio Pagella; Marco C Post; Catherine Rennie; Carlo Sabbà; Patrizia Suppressa; Pernille M Toerring; Sara Ugolini; Elisabetta Buscarini; Sophie Dupuis-Girod; Claire L Shovlin Journal: Orphanet J Rare Dis Date: 2020-06-29 Impact factor: 4.123
Authors: C L Shovlin; C M Millar; F Droege; A Kjeldsen; G Manfredi; P Suppressa; S Ugolini; N Coote; A D Fialla; U Geisthoff; G M Lenato; H J Mager; F Pagella; M C Post; C Sabbà; U Sure; P M Torring; S Dupuis-Girod; E Buscarini Journal: Orphanet J Rare Dis Date: 2019-08-28 Impact factor: 4.123
Authors: J M Mora-Luján; A Iriarte; E Alba; M A Sánchez-Corral; P Cerdà; F Cruellas; Q Ordi; X Corbella; J Ribas; J Castellote; A Riera-Mestre Journal: Orphanet J Rare Dis Date: 2020-03-02 Impact factor: 4.123